Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leslie A Washburn

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
JCO Oncology Practice|July 2, 2026
Advancing the Oncology Data Paradigm: Multisite Expansion of Structured Cancer Data Capture at the Point of CareChristopher D Vetter, Clare Gatten, Pooja Advani, et al.
JCO Precision Oncology|July 10, 2026
Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract CancersPriyanshi Shah, Anina Peersen, Vaibhav Sahai, et al.
The Oncologist|September 19, 2025
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective studyIoannis Kournoutas, Paulina Marell, Jennifer Gile, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
JCO Oncology Practice|July 2, 2026
Advancing the Oncology Data Paradigm: Multisite Expansion of Structured Cancer Data Capture at the Point of CareChristopher D Vetter, Clare Gatten, Pooja Advani, et al.
JCO Precision Oncology|July 10, 2026
Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract CancersPriyanshi Shah, Anina Peersen, Vaibhav Sahai, et al.
The Oncologist|September 19, 2025
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective studyIoannis Kournoutas, Paulina Marell, Jennifer Gile, et al.
Pageof 1